
News|Articles|October 6, 2023
EURETINA 2023: Safety and efficacy through week 48 in the Phase 2a STARLIGHT clinical trial
Author(s)Sydney M Crago
We spoke with Michael Singer, MD who provided an overview of his presentation, "MCO-010 Optogenetic Therapy to Treat Stargardt Disease: Safety and Efficacy through Week 48 in the Phase 2a STARLIGHT Clinical Trial"
Advertisement
The 23rd annual EURETINA Congress is underway in Amsterdam, the Netherlands. We spoke with Michael Singer, MD who provided an overview of his presentation, "MCO-010 Optogenetic Therapy to Treat Stargardt Disease: Safety and Efficacy through Week 48 in the Phase 2a STARLIGHT Clinical Trial."
Here's what he had to say about the meeting and his research.
Audio Transcript
Editor's note - This transcript has been edited for clarity.
Newsletter
Advertisement
Latest CME
Advertisement
Advertisement
















































